Reuters logo
BRIEF-‍Jupiter Orphan Therapeutics Inc says received orphan drug designation for its trans-resveratrol product Jotrol
August 22, 2017 / 12:57 PM / a month ago

BRIEF-‍Jupiter Orphan Therapeutics Inc says received orphan drug designation for its trans-resveratrol product Jotrol

Aug 22 (Reuters) -

* ‍jupiter Orphan Therapeutics Inc says receives orphan drug designation for its trans-resveratrol product Jotrol for treatment of Friedreich’s Ataxia​ Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below